VERY NICE GAINS ON GENE EDITING COMPANY EDITAS MEDICINE — TAKE PARTIAL PROFITS
This is the golden age of gene editing. Our view of gene editing company Editas Medicine (EDIT) is positive but a stock and a company are two different things. This stock has been highly pumped recently. This provided a trading opportunity from the short side. The stock was sold short
January 3, 2021